IQVIA Institute for Human Data Science

Our summary highlights from a virtual roundtable on Policy Proposals to Achieve Long-term Sustainability of Infused Biosimilars in the U.S. delves into critical challenges impacting the economic viability of biosimilars. Exhibit 7 highlights the implications of incorporating payer rebates into the Average Sales Price (ASP) calculation, which can strain providers' net cost recovery. To address this, policy adjustments could include modifying or even removing rebates from the ASP calculation specifically for biosimilars. This shift would align reimbursement more closely with providers' actual acquisition costs, supporting cost recovery and economic viability. It could also alleviate the pressure on manufacturers to deepen ASP discounts to cover provider costs. For those interested in shaping biosimilar policy, this summary offers critical insights. https://bit.ly/40oQjko

In a recent discussion at the Institute’s 2024 Pre-ESMO Symposium, Pilar de la Rocha Mur, Head of Europe, Global Clinical Operations at BeiGene, shares how advanced access to electronic medical records in the U.S. is reshaping clinical trial monitoring. With remote data access enabling faster enrollment and less need for on-site monitoring, this shift could be influencing sponsors to run more trials in the U.S. Learn how digital access is transforming clinical trials: https://bit.ly/4hiexmF. #Clinical Research

IQVIA Institute's report on The Global Use of Medicines 2024 provides an in-depth look at the evolving dynamics of #GlobalMedicine spending. Developed economies are set to see accelerated growth, propelled by new product launches and increased usage of existing branded medicines, although offset by patent expiries. Latin America, Eastern Europe, and parts of Asia are forecasted for robust growth, largely due to the rising adoption of novel treatments. Despite a significant reduction in projected spending on #COVID19 vaccines and therapeutics, the growth outlook to 2028 remains 2% higher than previous forecasts. As spending and volume trends vary across regions, the established markets will likely see more rapid growth, while Pharmerging regions are expected to grow through increased volume rather than higher-cost therapies. Understand how these trends will shape the global landscape for medicines in the coming years: https://bit.ly/3UuXeF1.

IQVIA Institute convened a roundtable with a multi-stakeholder panel to discuss the challenges impacting the long-term sustainability of infused #biosimilars. As these treatments continue to offer significant value, evolving the policies around their reimbursement is critical to maintaining progress. Key Highlights: - The current ASP-based reimbursement system is considered the main obstacle to the sustainability of infused biosimilars. - Meaningful policy reforms are needed, with all stakeholder perspectives taken into account. - Among the proposals discussed, the implementation of a provider reimbursement floor emerged as the most significant potential reform, although further analysis, consideration, and discussion are needed. Read the full summary highlights: https://bit.ly/3AlVU0f. 

In a clip from the 2024 Pre-ESMO Symposium, Dr. Josep Tabernero, Head of the Medical Oncology Department at Vall d’Hebron University Hospital, highlights the indispensable role of clinical research in cancer treatment. “All that we have achieved is through clinical research,” Dr. Tabernero emphasizes. He stresses that the advancements in cancer care we see today—and those we aim for in the future—are only possible because of a continued commitment to clinical trials and research. The future of oncology relies on this foundation to drive innovation and improve patient outcomes. Watch the full Pre-ESMO Symposium: https://bit.ly/3YdsaL4.

Our report on Rethinking Clinical Trial Country Prioritization highlights a notable rise in China's utilization for clinical trials, driven by China-headquartered companies. These companies are increasingly conducting single-country trials, resulting in a substantial shift in the global clinical trial landscape. From 2019 to 2023, China's share of clinical trials has seen a significant increase, particularly in oncology, non-oncology Phase I, and cell and gene therapy segments. While global trials with China sites have seen modest growth, the overwhelming majority of trials remain single-country, with China-headquartered companies focusing on leveraging their local resources. This surge reflects China's evolving role as a key player in the clinical trial ecosystem, reshaping the global approach to trial location strategy and presenting new opportunities and challenges for the pharma industry. Delve into more key findings: https://bit.ly/4hj3gCE.

The Key Context for CMS Prescription Drug Negotiations report reveals important trends in out-of-pocket (OOP) costs for Medicare Part D patients. While insulin drugs such as Novolog and Fiasp have average OOP costs under $200 annually, treatments such as Enbrel, Stelara, and Imbruvica see much higher costs, with over 40% of patients facing more than $2,000 annually for Enbrel and Stelara. For other selected drugs, most patients pay between $500 and $700 annually, with OOP costs rarely exceeding $2,000. While caps on insulin and OOP costs will help many, the full impact of government negotiation on overall OOP costs remains to be seen. Download the full report to learn more about the future of Medicare drug pricing: https://bit.ly/4eQNQUh.

Exhibit 8 from the Key Context for CMS Prescription Drug Negotiations report explains how #Medicare Part D formulary tiers shape patient cost-sharing. These tiers significantly impact what patients pay for their medications: -Preferred brands: Static co-pays ($40-$47) or co-insurance (16% to 25%) -Non-preferred brands: Co-insurance rates (40% to 50%) -Specialty tier drugs: High-cost drugs with a median co-insurance rate of 25% Understanding these tier structures is essential for managing out-of-pocket costs. Discover how these tier classifications influence patient expenses: https://bit.ly/3NC5zTD.

As we reflect on the ongoing efforts to fight breast cancer, it's important to highlight the progress being made in treatment and survival rates. According to the Global Oncology Trends 2024 report, five-year survival rates for breast cancer have improved from 89% in 2000–2007 to 91% in 2020, thanks to advancements in treating biomarker-identified subtypes with novel therapies. Key insights include: - HER2-low breast cancer: Once classified as HER2-negative, this subtype may respond to HER2-targeted therapies. - Triple-negative breast cancer: The use of checkpoint inhibitors in combination therapies has expanded treatment options. Continued innovation is critical to further improving patient outcomes. Read more: https://bit.ly/4f0x1pW.

IQVIA Institute's on-demand webinar reveals key findings from our report on Rethinking Clinical Trial Country Prioritization. This independent analysis examines trends in enrollment, trial characteristics, and country utilization over the past five years. Highlights include: - Expanding the footprint of #clinicaltrials on a global scale - Addressing capacity challenges in key therapeutic areas - Improving #patientrecruitment and retention strategies Watch now: https://bit.ly/4f7RJ71.